Phenobarbital and its Sodium Salt - IARC Monographs on the ...

Table 3 (contd)
Strain (sex) Initiator, dose, route
<strong>and</strong> duration
Sprague-
Dawley (M)
B[a]P, 4 mg/rat ig × 6
(24 h after PH)
Donryu (M) 3′-Me-DAB, 0.06%
diet, 3 weeks
CD1 (M) AAF, 0.02% diet,
2 weeks
ACI (M
<strong>and</strong> F)
Cycasin, 100 mg/kg
bw, ig × 1
CD (F) N-OH-AABP or
N-OH-FABP, 0.4
mmol/kg bw, ip × 1
(24 h after PH)
Sprague-
Dawley (M)
NDEA, 40 or 50
mg/kg bw, ip (18 h
after PH)
Wistar (M) NDEA, ~ 10 mg/kg bw
in water, 2, 4 or 6
weeks
Interval
between
initiator <strong>and</strong>
promoter
Dose <strong>and</strong> duration of PB or
NaPB <strong>and</strong> route
Promoting or anti-promoting effects
on preneoplastic or neoplastic
hepatocellular lesions
2 weeks PB, 0.05% diet, 50 weeks B[a]P given ig followed by PB
produced tumours in 6/15 rats;
PB alone, 0/10
2 weeks PB, 0.05% diet with initiator
<strong>and</strong>/or given as a promoter
for 35 weeks
1 week PB, 0.002–0.25% diet
(various concentrations),
78–84 weeks
1 week PB, 0.05% diet, up to 480
days
Inhibition of EAIs when given with
initiator; promotion when given after
initiation
Dose-dependent tumour-promoting
effects
γ-GT-positive foci; incidence
significantly greater in females than
in males
2 days PB, 0.05% diet, 64 weeks γ-GT-positive foci; no growth with
PB alone; growth initiated by
PH + PB
1 week PB 0.06% with cholinesufficient
diet for 6 or 7
weeks or choline-deficient
diet for 8 weeks
1 week PB, ~ 15 mg/kg bw per day
in water, 4, 6 or 8 weeks
γ-GT-positive foci; choline-sufficient
+ PB, increased; choline-deficient
+ PB, synergistic promoting action
PB treatment reduced latency for
development of neoplastic nodules by
3–6 months
Reference
Kitagawa et al.
(1980)
Narita et al.
(1980)
Peraino et al.
(1980)
Uchida &
Hirono (1981)
Shirai et al.
(1981)
Shinozuka
et al. (1982)
Barbason et al.
(1983)
188
<strong>IARC</strong> MONOGRAPHS VOLUME 79